Medical Assistant

AYMAN OMAR, MD, PhD, MSc (Oxon), LMCC, DABPN

Email:*********@*****.***

https://www.linkedin.com/in/aymanomarmd

www.BrainTumorExperts.org

Cell: 224-***-****

CURRENT TITLE:

**/**** - ******* *****al Director, Neurology Inpatient Program Neurology Inpatient Program

Wellington Regional Medical Center and Institute for Minimally Invasive Therapy (IMIT)

Wellington, FL

5/2013 – Present President and Founder

Neurology and NeuroOncology Consultant, LLC

Providing specialized consulting services (Private Practice) in Neurology, Vascular Neurology and Neurological Oncology EDUCATION

Medical School

10/1986 - 12/1992 Doctor of Medicine (MBChB) (Awarded Medical Degree with Honors

University of Cairo

Cairo, EGYPT

Page 1 of 32

Graduate Studies

10/2014 - 10/2015 Master of Science (MSc) in Endovascular Neurosurgery University of Oxford

Nuffield Department of Surgery

St. Peter’s College

Oxford, UK

09/1999 - 10/2002 Doctorate in Philosophy (PhD) (GPA: 3.83/4.0) Neuroscience / Cellular and Molecular Medicine

University of Ottawa

Faculty of Graduate and Postdoctoral Studies (FGPS) Ottawa, CANADA

01/1998 - 09/1999 Master of Science (MSc), Anatomy and Neurobiology

(Recommended to Ph.D. Program due to exceptional progress without completion of a Masters thesis)

University of Ottawa

Dept. of Cellular and Molecular Medicine

Ottawa, CANADA

06/1995 - 10/1995 Program of Study, Lab Technology and Electron Microscopy Seneca College of Applied Arts and Technology

Toronto, ON, CANADA

Premedical

01/1985 - 01/1986 General Certificate of Education (GCE 6As and 2Bs) University of London, School Examinations Board

London, UK (Through the British Council in Stockholm and Cairo) 10/1982 - 7/1985 International Baccalaureate (IB) (completed 3 year program of study)

Norra Real Gymnasium - High School

Stockholm, SWEDEN

Page 2 of 32

CLINICAL TRAINING

Clinical and Research Fellowships

10/2014 - 10/2015 Fellow (Specialist Registrar) in Endovascular Neurosurgery University of Oxford Hospitals NHS Trust

John Radcliffe Hospital

Trained under direction of Prof. James Byrne and Dr. David Corkill Oxford, UK

Training in endovascular techniques: Diagnostic cerebral angiograms, spinal angiography techniques, coiling of aneurysms, flow diverters such as pipeline embolization device, woven endobridge device (WEB), use of liquid embolics for head and neck tumor embolization, AVM and dural AVF embolization, etc. 7/2014 - 9/2014 Mini-fellowship / Course in Epilepsy (3 months) Cleveland Clinic Foundation

Department of Neurology, Epilepsy Center

Trained under Drs. Najm, Alexopoulos and Burgess

Cleveland, OH

Training in Epilepsy, epilepsy surgery, Electroencephalography both adult and pediatric, invasive testing including depth electrodes and subdural grid interpretation, Evoked Potential interpretation, Polysomnography, Intraoperative monitoring and clinical neurophysiological techniques.

7/2006 – 7/2008 Clinical Fellow and Research Fellow in Neurological Oncology University of Toronto

Trained under direction of Dr. Warren Mason

Princess Margaret Hospital, Pencer Brain Tumor Center Department of Medicine, Division of Hematology and Oncology Toronto, ON, CANADA

07/2000 – 7/2002 Canadian Institutes of Health Research (CIHR/MRC) Fellow Canadian Institutes of Health Research

Ottawa Health Research Institute, Ottawa Hospital

Trained under direction of Prof. Bin Hu

University of Ottawa

Division of Neurosciences

Page 3 of 32

Residency and Chief Residency

07/2005 - 7/2006 Chief Resident in Neurology

University of Missouri - Columbia

Harry S. Truman Memorial Veterans Administration Hospital Columbia, MO, USA

07/2003 - 7/2005 Resident in Neurology

University of Missouri - Columbia, MO, USA

Harry S. Truman Memorial Veterans Administration Hospital, Columbia, MO, USA

My responsibilities included admitting, evaluating and managing patients on Neurology inpatient, consult, acute stroke call, EMG, EEG, sleep studies etc. Additional privileges at the Rusk Rehab as well as Columbia Regional Hospital.

Internships

6/1/1993 - 10/31/1993 House Officer (Rotational Intern) 12/1/1995 - 6/30/1996 Cairo University Teaching Hospitals Received intensive 12 months training in the following areas: Neurosurgery and Neuro-traumatology: 8 wks; General and Vascular Surgery: 8 wks; Orthopedics: 4 wks; Emergency Surgery: 4 wks; OB/GYN: 8 wks; General Pediatrics and neonatal intensive care: 8 wks; General Internal Medicine: 8 wks.

07/2002 – 6/2003 Intern in Internal Medicine

University of Missouri – Columbia

Harry S. Truman Memorial Veterans Administration Hospital Columbia, MO, USA

Page 4 of 32

WORK EXPERIENCE:

8/ 1/ 2013 - 12/1/2017 Attending Neurologist (Locums) CompHealth and Vista Staffing

7/29/2013 - 7/31/2015 Adjunct Assistant Professor of Neurology Southern Illinois University School of Medicine

State of Illinois

Springfield, IL

6/7/2010 – 7/29/2013 Program Director and Division Chief of Neurological Oncology Assistant Professor of Clinical Neurology

Southern Illinois University School of Medicine

Springfield, IL

Built the first NeuroOncology Program in Central and Southern Illinois

6/7/2010 – 7/29/2013 Staff Attending Neurologist, Dept. of Neurology St. John’s Hospital Sisters Network

Springfield, IL

6/7/2010 – 7/29/2013 Staff Attending Neurologist, Dept. of Neurology Memorial Medical Center

Springfield, IL

6/7/2010 – 7/29/2013 Program Director, Division of NeuroOncology Simmons Cancer Institute (SIU School of Medicine)

Springfield, IL

7/1/2009 - 3/31/2010 Clinical Assistant Professor of Neurology University of Chicago, Pritzker School of Medicine Biological Sciences Division

Chicago, IL

8/1/2008 - 3/31/2010 Attending Neurologist and NeuroOncologist NorthShore University HealthSystem

Evanston, IL

Page 5 of 32

01/1997 - 06/1997 Internal Medicine Physician (Private Practice) Nile Badrawi Hospital

Cairo, Egypt

My responsibilities included management of inpatients as well as outpatients (including neurology, cardiology, pulmonology, oncology, gastroenterology, and a wide variety of general internal medicine cases). In addition, I was responsible for the monitoring of 30 regular hemodialysis patients as well as post-op care of renal transplant recipients. The department received 30-50 patients daily including those admitted through HMO’s covering the Middle East region, (Middle East Medicare Plan).

07/1996 - 10/1996 Internal Medicine Physician (Private Practice) Al-Salam Hospital

Cairo, Egypt

My responsibilities included management of patients admitted to the ICU and CCU in addition to the Dialysis Unit, where I monitored patients and performed preoperative workup and postoperative care of renal transplant recipients. LICENSURE:

1. State of Florida, Physician and Surgeon License - Active 2. United Kingdom, General Medical Council, Full Registration with a license to practice, granted January 31, 2015, GMC # 7480950

3. State of Missouri, Permanent Physician and Surgeon License, issued October 2013 4. State of Kansas, Permanent Physician and Surgeon License, issued March 2014 5. State of Illinois, Physician and Surgeon Permanent License, 2008 Page 6 of 32

6. State of Indiana, Permanent Physician License, License #01062696A, 2006 7. Canada, Province of Ontario, Member, College of Physicians and Surgeons of Ontario, License # 85030, 2006 (Expired)

8. Egypt National Medical License, General Medical License (Full Registration), Ministry of Health, Egypt, 1996 (Permanent)

9. State of Missouri Temporary License, Physician and Surgeon Temporary License for training, USA, 2002 - 2006 (Expired)

CERTIFICATIONS:

1. The international English language testing system (IELTS) (University of Cambridge English Language Exam) Scored Band 8 out of 9: First attempt November 2014 2. Radiation Protection and Radiation Physics course (4 months) - Completed January 2015. Course accredited by the UK Royal Society of Radiologists 3. Good Clinical Practice Training: John Radcliffe Hospital, Oxford, UK, May 2015 4. Oxford Aneurysm Treatment School course: Passed 2015 5. European Course on Minimally Invasive Neurological Therapy (ECMINT1): Passed 6. European Course on Minimally Invasive Neurological Therapy (ECMINT1.2): Passed June 24-27, 2015

7. Certified, National Institutes of Health Stroke Scale, National Stroke Association, 10/13-10/15

8. Board Certified, American Board of Psychiatry and Neurology, Jan. 14, 2011 9. Licentiate of the Medical Council of Canada (LMCC), 2006 10. Medical Council of Canada Qualifying Examination, Part II (MCCQE II), 2005 Page 7 of 32

11. Medical Council of Canada Qualifying Examination, Part I (MCCQE I), May, 2000 12. Medical Council of Canada Evaluating Examination (MCCEE), September, 1999 13. Certified by the Educational Commission for Foreign Medical Graduates (ECFMG),USA

(1998)

14. United States Medical Licensing Examination (USMLE), Step 3, 2008 15. United States Medical Licensing Examination (USMLE), Step 2CS, 2008 16. United States Medical Licensing Examination (USMLE), Step 2, March, 1996 17. United States Medical Licensing Examination (USMLE), Step 1, June, 1995 18. Cert. Basic Cardiac Life Support (BCLS) Provider, St. John Ambulance, Ottawa, 1999, Re- certified in 2002 and 2004 and February 6, 2014 and UK BLS and PLS Certified in June 2015.

19. Cert. Advanced Cardiac Life Support (ACLS) Provider, American Heart Association, 1999, Re-certified in 2002, 2004 and April 13, 2014

20. Cert. Advanced Trauma Life Support (ATLS) Provider, American College of Surgeons, April, 2000

21. Test of English as a Foreign Language (TOEFL); score: 290 (CBT; 99th percentile) 22. Test of Spoken English (TSE), February 2000; score: 60 (99th percentile) 23. Completed course on Minimizing Healthcare Errors with Crew Training International designed for healthcare professionals using fighter jet pilot standards. 24. Completed New Formulations for Anti-Epileptic Drugs, AB Comm. Inc., May, 2004 25. Certified in Institutional Review Board (IRB) policies and procedures for conducting clinical research (12/31/05)

26. Certified in Health Sciences Health Insurance Portability and Accountability Act (HIPAA) guidelines (12/31/2005)

27. National Institutes of Health (NIH), National Cancer Institute (NCI) Investigator number assigned since 2008

28. Successfully completed the Collaborative Institutional Training Initiative (CITI), 2011. This Page 8 of 32

is an international course designed to educate researchers on international, local and FDA regulations designed for the appropriate and ethical conduct of research involving human subjects. Course includes 28 modules and additional modules for IRB members (completed all modules).

29. Ethics Training for University Employees (Online Course), 2011 and 2012 30. Certified in NovoTTF-100A alternating electric current delivery system used to treat recurrent glioblastomas through placement of transducer arrays directly on a patients skull. Established the first and only ‘clinical center of excellence’ for NovoTTF-100A system in central and southern Illinois and one of only ~40 centers nationwide (http:// www.novottftherapy.com/patients-centers.php)

HONORS & DISTINCTIONS:

1. Listee, Marquis Who’s Who in the World, 2018, 2019 2. Named “Medical Innovator” for 2013 by the Sangamon County Medical Society and the Springfield Mayor for “Innovations in the treatment of brain and spinal cord tumors”. Honored in an award ceremony by the Mayor of Springfield, Mike Houston on March 7, 2013.

3. Awarded Founding Knowledge Editor by HealthTap (A global interactive health care company) for contributing to the development of the first artificial intelligence computer algorithm (Dr.AI) that helps guide patient care remotely (January 2017). 4. Awarded Chief Residency in Neurology - University of Missouri - Columbia (2005-2006) 5. Travel Fellowship from the American Neurological Association (nation-wide competition) to attend ANA meeting in Toronto, ON, Canada; Funding: $500.00, October 2-6, 2004

6. Scored in the top 1% in North America in the Neurology Residency In-Service Training Exam (RITE), American Academy of Neurology, 2003 and 2004 Page 9 of 32

7. Selected as one of the top 150 internationally-trained physicians in the Ontario IMG Program Entrance Exam, University of Toronto, December, 2001 8. Travel Award from the University of Ottawa, Faculty of Graduate and Post-Doctoral Studies to present poster at the Society for Neuroscience, 31st annual meeting, San Diego, Ca, November, 2001

9. Prize for Outstanding Achievements, Ottawa Hospital Foundation, Ottawa, Canada, November, 2000

10. Post-Doctoral Fellowship Award, Canadian Institutes of Health Research (CIHR) under the Canadian Neurotrauma Research Program (CNRP); Ranked: 6th nationwide, June, 2000; Title of Project: Rapid Tissue Remodeling in Dentate Gyrus of Adult Rat Hippocampus Following Excitotoxic Injury. Funding: $120,000; Fellowship Director: Bin Hu, MD, PhD

11. Excellence Scholarship in Science and Engineering (PhD), University of Ottawa, Faculty of Graduate and Post-Doctoral Studies; Funding: $15,000, June, 2000 12. Graduate Admission Scholarship in Science and Engineering (PhD), University of Ottawa, Faculty of Graduate and Post-Doctoral Studies; Funding: $5,000, January, 2000 13. Travel Award from the University of Ottawa, Faculty of Graduate and Post-Doctoral Studies to present poster at the Society for Neuroscience, 29th annual meeting, Miami Beach, FL, October, 1999

14. Awarded Medical Degree with Honors, University of Cairo, December, 1992 15. Scholarship of Academic Excellence, University of Cairo, 1987-1992, awarded annually 16. Travel Award from the IFMSA (World Health Organization) to attend Emergency Surgery Clerkship at University Clinical Hospital, Zaragoza, Spain, 1991 17. Admission Scholarship, University of Cairo, Faculty of Medicine, 1986 18. Admission Scholarship, American University in Cairo, Mechanical Engineering, 1985, declined.

Page 10 of 32

19. MEDIA COVERAGE

Peoria Journal Star. Electric field treatment takes aim at brain cancer. December 26, 2012 http://www.pjstar.com/article/20121226/News/312269854 State Journal Register, Springfield, IL February 13, 2013. Medical innovators to be honored March 7. News about being selected for the medical innovator award. State Journal Register, Springfield, IL December 3, 2012.. Electric fields extend life for some brain cancer patients. Read more: http://www.sj-r.com/article/20121203/News/ 312039867#ixzz389aJ5V8E

Aspects Magazine. (Featured on Cover). January 19, 2013. Target: Tumors http://www.siumed.edu/pubs/aspects/36-1/feature1.html Simmons Cancer Institute Newsletter, Winter 2012. A new standard of care for Glioblastoms. http://www.siumed.edu/cancer/pdf/newsletter/Winter2013.pdf Brainscan, Fall 2006. Profile Article for the Pencer Brain Trust. http:// www.pencerbraintrust.com/downloads/newsletters/brainscan_fall06.pdf Sangamon County Medical Society July/August 2013 Newsletter. Eleven Medical Professionals

Honored at Medical Innovators Program, Ayman Omar, M.D., Ph.D., SIU School of Medicine, for his novel approaches to treat brain and spinal cord tumors. http:// www.scmsdocs.org

Sangamon County Medical Society. Medical Innovators 2013. http://www.scmsdocs.org/pdf/ medinnovators2013.pdf

Page 11 of 32

RESEARCH AND ACADEMIC FUNDING:

• Principal Investigator (authored study design and protocol): Bevacizumab in combination with alternating electric fields for the treatment of recurrent glioblastoma NovoCure, Inc., Portsmouth, NH

Developer of FDA-approved NovoTTF Technology

Funding: $5000

• Postdoctoral Fellowship Award (National Award)

Canadian Institutes of Health Research (CIHR)

Funding: $120,000, June 2000

• Excellence Scholarship in Science and Engineering University of Ottawa

Funding: $15,000, June 2000

• Travel Award (National award competition – 4 selected) American Neurological Association

Attended ANA meeting in Toronto, ON, CANADA

Funding: $500, 2004

• Travel Award to present research findings at Society for Neuroscience, San Diego Meeting

University of Ottawa

Funding: $500, 2001

• Travel Award to present research findings at Society for Neuroscience, Los Angeles Meeting

University of Ottawa

Funding: $500, 1999

• Graduate Admission Scholarship in Science and Engineering (PhD) University of Ottawa

Funding: $5,000, January, 2000

• Travel Award to attend Emergency Surgery Clerkship at University Clinical Hospital, Zaragoza, Spain, 1991

Page 12 of 32

World Health Organization (IFMSA)

Funding: Full room and board for 1 month.

. Scholarship for Academic Excellence

University of Cairo

Funding: Monthly Stipend, 1987-1992 (award renewed annually)

• University of Cairo

Admission Scholarship

Funding: Monthly Stipend, 1986-1987

• American University in Cairo

Admission Scholarship, Mechanical Engineering

Funding: University Tuition Fees, 1985 (Declined in favor of Medical School) RESEARCH:

Basic Science Research

07/2000 – 7/2002 CIHR (MRC) Fellow

Canadian Institutes of Health Research

Ottawa Health Research Institute, Ottawa Hospital

University of Ottawa

Division of Neurosciences

Successfully competed and obtained funding (~$120,000) from the premier national research funding agency in Canada, the Canadian Institutes of Health Research (formerly the Medical Research Council of Canada). My grant proposal was ranked 6th nationwide. My project focused on investigating the molecular mechanisms governing stem cell proliferation and differentiation in the dentate gyrus of rats following traumatic and ischemic cell injury. I was able to show for the first time that sodium-potassium pump inhibition up-regulates proliferative activity of stem cells in the subgranular zone of the dentate gyrus. I also showed that in the early stages post-injury, precursor cells undergo an accelerated rate of migration towards areas of cell injury. These findings may have important functional implications in neural network Page 13 of 32

reconstruction following brain damage. Techniques used in this project include electrophysiological recordings from acute brain slices, immunofluorescence, in situ hybridization, confocal imaging, digital image analysis and stereotactic CNS micro-infusions. 07/1997 - 07/2000 Research Assistant and PhD Student University of Ottawa

Loeb Health Research Institute, Ottawa Hospital

Division of Neurosciences

My research focused on elucidating the mechanisms of ischemic neuronal injury. I was successful in developing a novel in-vivo model for acute ischemic stroke which involved the stereotactic infusion of ouabain (a sodium-potassium ATPase pump blocker) with fluorescent molecular probes into the dentate gyrus of adult rats. This model allowed for the delineation of the cellular and molecular responses of neurons to ischemic injury, and allowed the visualization of lipid bilayer and DNA conformational changes post-injury. I subsequently utilized this model to study the mechanisms of mannitol-based neuroprotection particularly its effects on sodium and potassium ion regulation in neurons.

Clinical Research (Selected trials as PI or co-investigator) Glioblastoma Multiforme

• Avastin and Temozolomide following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study

Avastin, a monoclonal antibody angiogenesis inhibitor is added to the standard of care treatment of temozolomide chemotherapy to determine the safety and effectiveness of the combination. Patients may receive treatment until progression or unacceptable toxicities.

• Avastin, Temozolomide, Bevacizumab and RT followed by Temozolomide and Avastin versus Avastin and Temodar vs. RT/TMZ + placebo followed by TMZ plus placebo for newly diagnosed GBM: International, muticenter, randomized, double blinded placebo controlled trial (AVAGLIO)

Study name: AvaGlio (Avstin in Glioblastoma). This is an International phase III trial (the largest trial of its kind for the treatment of Glioblastoma (GBM), the most aggressive brain cancer) Page 14 of 32

examining the efficacy of adding Avastin (a drug that chokes off blood supply to brain cancer) to standard tx. for newly diagnosed GBM patients. Attended European Investigator meeting in Vienna, Austria (June 15-18, 2009) representing Northshore University HealthSystem, USA as one of the US study sites that participated in this international trial (one of 143 centers worldwide). In Vienna, I was able to point out a critical problem with the study design that was previously overlooked by the international study team and as a result an amendment was resubmitted to the FDA for approval

• A Phase II Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme: Phase II/III

CDX110 is a vaccine which recognizes the protein EGFRvIII in GBM. The purpose is to determine effectiveness and side effects of adding CDX-110 to the standard of care treatment for GBM. Patients will receive Temodar days 1-5 of a 28-day cycle and the CDX-110 vaccine on day 21 of each cycle. Treatment may continue with Temodar for up to one year and the vaccine continues until progression or unacceptable toxicities.

• Temozolomide Alone and in Combination with Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy for Glioblastoma Multiform

The purpose of this study is to compare treatment of temozolomide with the combination and the above mentioned drug to determine the efficacy and safety of these combinations.

. A Phase I Study of Temozolomide and RAD001C in Patients With Malignant Glioblastoma Multiforme, Sponsor: National Cancer Institute of Canada Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving temozolomide together with everolimus may kill more tumor cells.

This phase I trial is studying the side effects and best dose of everolimus when given together with temozolomide in treating patients with newly diagnosed, recurrent, or progressive malignant glioblastoma multiforme.

• Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma, Sponsor: Eli Lilly and Company

This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme). Page 15 of 32

• The Temozolomide RESCUE STUDY: A Phase II Trial of Continuous (28/28) Dose- Intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma, Sponsor: Schering- Plough, Schering Canada, Inc.

The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m2) for up to 12 months may overcome resistance and be effective in the management of adult patients with malignant glioma who have failed following at least 2 cycles

(2 months) of conventional 5-day (5/28) cycles of high-dose temozolomide (150-200 mg/m2). Recurrent Glioblastoma Multiforme

• Ayman Omar, MD, Principal Investigator. NovoTTF100A in combination with Bevacizumab for the treatment of recurrent glioblastoma. Grant for $5000 from NovoCure. May 2013.

This project involves developing a novel treatment approach for the treatment of recurrent GBM patients. The method involves combining the NovoTTF-100A system which delivers alternating electric fields to the brain tumor with bevacizumab, a VEGF inhibitor.

• Phase III, Randomized, Parallel Group, Multicenter Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib (Recentin, AZD2171) Monotherapy and the Combination of Cediranib with Lomustine to the Efficacy of Lomustine Alone Cediranib is a highly potent and selective VEGF signaling inhibitor that targets all three VEGF receptors.2 VEGF signaling is a key driver of angiogenesis - the formation of new blood vessels that tumors need to grow and spread.

Low Grade Gliomas

• Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study, Sponsor: European Organization for Research and Treatment of Cancer and the National Cancer Institute of Canada.

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more Page 16 of 32

effective than temozolomide in treating gliomas.

This randomized phase III trial is studying radiation therapy to see how well it works compared to temozolomide in treating patients with gliomas. Metastatic Brain Cancer

• Evaluating the Treatment Effects of Surgery plus GLIADEL Wafer in Patients with Metastatic Brain Cancer

The purpose of this study is to find out the effects of surgery and the placement of Gliadel wafers on the neurocognitive function of patients with metastatic brain cancer. NeuroOphthalmology Research

• Role of tetracycline in the treatment of chronic progressive external ophthalmoplegia

(CPEO)". Principal Investigator: Lenworth Johnson, Professor of Ophthalmology

(Neuro-Ophthalmology) and Neurology, University of Missouri - Columbia. Co- Investigator: A.I. Omar, Neurology Chief Resident, University of Missouri - Columbia. University of Missouri IRB Project #: 1059518. (1/06/ - 7/06) This is a retrospective analysis of the effect of tetracycline antibiotics on ocular motility in chronic progressive external ophthalmoplegia. CPEO is a hereditary mitochondrial myopathy that results in progressive weakness of the extraocular muscles involved in eye movement. Patients with CPEO have limited eye movements which can result in double vision, difficulty with reading and gait disturbance. These symptoms are chronic and progressive, as the name implies, and can be debilitating for patients affected by this condition. To date, there are no available effective treatment options for this disease. Some of our patients have been treated with tetracycline and have had apparent improvement in eye movement. After retrospectively analyzing the data, we have shown for the first time that tetracycline can play a role in improving ocular motility and in delaying progression of the disease. TEACHING EXPERIENCE:

Wellington Regional Medical Center and the Edward Via College of Osteopathic Medicine. Internal Medicine Residency Program - Neurology Rotation 12/2017 - Present

Teaching IM residents and Medical Students during 1 month Neurology Rotation Page 17 of 32

Southern Illinois University School of Medicine

June 2010 - July 2015

Author of senior clinical competency exam case, “Intracranial hypotension secondary to a spinal CSF leak”, July 2013. This case is part of the 4th year medical student clinical competency assessment.

Headache lecture to family practice residents 5/8/13 MS lecture to Internal Medicine Residents on 5/20/13 Resident teaching on the inpatient service

Resident clinic supervision.

Teaching of Neuroscience course for Neurology Residents Medical Student teaching: CNS tumors lecture

Medical student teaching on inpatient and outpatient services Resident supervision during Journal Clubs

Examiner: Resident NEX exams (American Board of Psychiatry and Neurology) Director of Neurological Oncology resident elective rotation Director of NeuroImmunology and Multiple Sclerosis resident elective rotation NeuroOncology: The Essentials, 5 1-hr lectures from March 19-23, 2012 to Neurology residents Lectures on Multiple Sclerosis to Neurology residents February 21, 2012 Lectures on Neurologic complications of HIV to Neurology residents, May 2012 Lectures on evaluation and management of pituitary tumors to Neurology Residents at SIU, May 2012

University of Chicago

July 1, 2009 – March 31, 2010

Teaching Medical Residents and Medical students on in- and outpatient services Page 18 of 32

Northwestern University, Feinberg School of Medicine August 1, 2008 – June 30, 2009

Resident, medical student and physician assistants teaching /supervision on medical wards as well as classroom lectures, bedside demonstrations and supervision of patient related procedures. University of Toronto, Faculty of Medicine

July 1, 2006 – June 30, 2008

Supervised residents as Fellow in Neurological Oncology Supervised a medical student from Germany for 1 month as part of a University of Toronto international medical student exchange program

University of Missouri - Columbia

July 1, 2002 – June 30, 2006

Taught medical students as floor and consulting Neurology Resident. Taught Introduction to Physical Diagnosis and Advanced Physical Diagnosis (APD) to 1st and 2nd year medical students

CSF Dynamics and Intracranial Pressure course, February 2, 2006, Posted online WebCT, University of Missouri – Columbia

University of Ottawa, Faculty of Medicine

January, 1998 – June, 2002

Teaching Assistant: Neurology Block (MED2104; Course Director: Prof. W. Hendelman, 01/1999 - 02/2000)

This position involved teaching the "Neurology block" to 2nd year medical students which included theoretical Neuroanatomy, Neurology, and Neuroradiology case studies as well as cadaver specimens and laboratory demonstrations.

Supervised medical students and lab trainees in Neuroscience research techniques including immunofluorescence, tissue processing, stereotactic brain infusions, confocal microscopy techniques (Laboratory of Bin Hu, MD, PhD).

Page 19 of 32

CME (selected)

04/29/2009 Annual Meeting - 5PC.005:

Contact this candidate